PRTC PureTech Health plc

Nasdaq puretechhealth.com


$ 18.70 $ 0.46 (2.65 %)    

Friday, 17-Oct-2025 16:02:25 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 18
$ 17.96
$ 17.00 x 1
$ 19.35 x 1
$ 17.26 - $ 18.00
$ 13.30 - $ 24.99
3,493
na
8.04B
$ 0.71
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 puretech-presents-phase-2b-open-label-extension-data-showing-deupirfenidone-stabilizes-lung-function-in-ipf-with-favorable-tolerability

Patients who switched from placebo or pirfenidone to deupirfenidone in the open-label extension study achieved stabilization of...

 puretech-health-h1-eps-019-down-from-015-yoy-sales-185m-up-from-28800k-yoy

PureTech Health (NASDAQ:PRTC) reported quarterly losses of $(0.19) per share. This is a 26.67 percent decrease over losses of $...

 puretech-healths-founded-entity-vedanta-biosciences-says-its-candidate-ve202-did-not-meet-primary-endpoint-in-phase-2-collective202-study-for-treatment-of-uc-patients

VE202 was well tolerated, with no reports of treatment-related serious adverse eventsAdditional analyses from COLLECTiVE202 to ...

 puretech-health-launches-celea-therapeutics-to-transform-treatment-of-respiratory-diseases

Former Teva North America CEO Sven Dethlefs, PhD, to lead CeleaPureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech...

 why-this-biotech-stock-just-doubled-in-a-single-day

Vor Biopharma shares surge 43% after licensing deal, $175M raise, and CEO transition.

 puretech-presents-phase-2b-data-for-deupirfenidone-at-ats-2025-showing-statistically-significant-slowing-of-ipf-progression-with-durable-effect-over-52-weeks-favorable-safety-profile-and-plans-for-fda-meeting-and-phase-3-trial-launch-by-end-of-2025

Deupirfenidone 825 mg TID slowed lung function decline in people with idiopathic pulmonary fibrosis (IPF) to the range expected...

 puretech-health-fy-eps-021-up-from-024-yoy-sales-483m-up-from-333m-yoy

PureTech Health (NASDAQ:PRTC) reported quarterly earnings of $0.21 per share. This is a 187.5 percent increase over losses of $...

 puretech-health-confirms-ongoing-discussions-with-nordic-capital-regarding-possible-cash-offer-for-entire-share-capital-with-a-decision-expected-by-may-5-2025

The Board of PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company") notes the recent pres...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION